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Abstract Sarcopenic obesity is characterised by
high fat mass, low muscle mass and an elevated
inflammatory environmental milieu. We therefore
investigated the effects of elevated inflammatory
cytokine TNF-a (aging/obesity) and saturated fatty
acid, palmitate (obesity) on skeletal muscle cells in the
presence/absence of EPA, a-3 polyunsaturated fatty
acid with proposed anti-inflammatory, anti-obesity
activities. In the present study we show that palmitate
was lipotoxic, inducing high levels of cell death and
blocking myotube formation. Cell death under these
conditions was associated with increased caspase
activity, suppression of differentiation, reductions in
both creatine kinase activity and gene expression of
myogenic factors; IGF-II, IGFBP-5, MyoD and
myogenin. However, inhibition of caspase activity
via administration of Z-VDVAD-FMK (caspase-2),
Z-DEVD-FMK (caspase-3) and ZIETD-KMK (cas-
pase 8) was without effect on cell death. By contrast,
lipotoxicity associated with elevated palmitate was
reduced with the MEK inhibitor PD98059, indicating
palmitate induced cell death was MAPK mediated.
These lipotoxic conditions were further exacerbated in
the presence of inflammation via TNF-a co-adminis-
tration. Addition of EPA under cytotoxic stress (TNF-
a) was shown to partially rescue differentiation with
enhanced myotube formation being associated with
increased MyoD, myogenin, IGF-II and IGFBP-5
expression. EPA had little impact on the cell death
phenotype observed in lipotoxic conditions but did
show benefit in restoring differentiation under lipo-
toxic plus cytotoxic conditions. Under these condi-
tions Id3 (inhibitor of differentiation) gene expression
was inversely linked with survival rates, potentially
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indicating a novel role of EPA and Id3 in the
regulation of apoptosis in lipotoxic/cytotoxic condi-
tions. Additionally, signalling studies indicated the
combination of lipo- and cyto-toxic effects on the
muscle cells acted through ceramide, JNK and MAPK
pathways and blocking these pathways using
PD98059 (MEK inhibitor) and Fumonisin B1 (ce-
ramide inhibitor) significantly reduced levels of cell
death. These findings highlight novel pathways asso-
ciated with in vitro models of lipotoxicity (palmitate-
mediated) and cytotoxicity (inflammatory cytokine
mediated) in the potential targeting of molecular
modulators of sarcopenic obesity.
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Introduction
The two greatest epidemiological trends of modern
times are the rapidly advancing age of the worldwide
population and the obesity epidemic. Ageing is
accompanied by changes in body composition char-
acterised by a relative decline in muscle mass
(Aniansson et al. 1983) and an increase in fat mass
(Lara-Castro et al. 2002), a condition termed sar-
copenic obesity (SO) (Roubenoff 2004; Zamboni et al.
2008). The prevalence of sarcopenic obesity is thought
to account for 25% of the population aged over 60
(Batsis et al. 2016) with a greater prevalence reported
in men (42.9%) than women (18.1%) (Batsis et al.
2014). A recent meta-analysis including 35,287 par-
ticipants and 14,306 deaths, suggested that individuals
with SO have a 24% increased risk of all-cause
mortality compared to those without SO (Tian and Xu
2016). With a global rise in ageing and obesity levels,
it is likely that this condition will represent a growing
clinical and financial burden for the health care
systems of developed countries (Sousa et al. 2016).
Independently, excess adiposity and reduced muscle
mass lead to adverse metabolic effects (e.g., hyperten-
sion, dyslipidaemia, insulin resistance). A combination
of increased adiposity and reduced lean mass, engen-
dered by ageing, may therefore contribute further to the
worsening of metabolic impairments. Furthermore, the
combination of low muscle mass and strength with
obesity are further associated with a pro-inflammatory
state, where adipocytes actively secrete increased
concentrations of pro-inflammatory cytokines (Fan-
tuzzi 2005; Mohamed-Ali et al. 1998), which stimulate
further muscle catabolism (Hotamisligil 1999a, b)
thereby activating a vicious cycle culminating in
accelerated sarcopenia, additional adiposity and ulti-
mately, physical disability.With age there is also a local
increase in the production of inflammatory cytokines by
skeletal muscle (Greiwe et al. 2001; Leger et al. 2008).
Elevated levels of cytokines have been shown to predict
accelerated decline of muscle strength and increased
risk of early mortality in older individuals (Cappola
et al. 2003; Ferrucci et al. 1999; Harris et al. 1999).
However, the underlying mechanisms of morbidity and
early mortality are poorly understood.
Circulating free fatty acids (FFAs) are elevated in
obese adults (Reaven et al. 2004) and in aged muscle
with increased fat infiltration, suggesting a connection
between a gain in fat mass, muscle triglyceride content
and inflammation with age (Zamboni et al. 2008). In
particular, the saturated free fatty acid, Palmitate
(C16H32O2) reduces insulin-stimulated phosphoryla-
tion of Akt (pAkt)—a key molecule in the insulin-like
growth factor (IGF) signalling pathway, which acts
potently to regulate protein synthesis, skeletal muscle
regeneration and differentiation (Egerman and Glass
2014). In contrast, studies have described the potential
anti-inflammatory health benefits of n-3 polyunsatu-
rated fatty acids such as eicosapentaenoic acid
(C20H30O2; EPA) with potential benefits for atrophy-
ing skeletal muscle (Babcock et al. 2002; Magee et al.
2008). Indeed, in murine models of cachexia, EPA
treatment caused a reduction in the rate of skeletal
muscle protein loss (Tisdale and Dhesi 1990; White-
house et al. 2001;Whitehouse andTisdale 2001)which
was associated with a downregulation of the ubiquitin–
proteasome pathway (Whitehouse and Tisdale 2001).
Additionally, EPA treatment has been shown to
attenuate the proteolytic and apoptotic effects of
cachectic factors in fully differentiated mouse C2C12
myotubes (Smith et al. 1999; Smith and Tisdale 2003).
Adult skeletal muscle is terminally differentiated,
therefore any repair and regeneration of the muscle is
dependent on resident satellite or infiltrating stem cells
(Cooper et al. 1999). The ability of these cells to
replicate and to fuse is dependent on the local growth
factor/cytokine environment (Saini et al. 2006, 2009;
Sharples et al. 2015; Sharples and Stewart 2011;
Sharples et al. 2016). Furthermore, altered cytokine
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levels have relevance in the pathogenesis of atrophy
by impeding regenerative processes and stimulating
protein catabolism. It is therefore conceivable, in
conditions of SO, that alterations in local levels of
FFAs and concomitant changes in growth factors and
cytokines may contribute to declining muscle mass
and strength. Previous findings led us to hypothesise
that palmitate potentiates whereas EPA protects
against skeletal muscle damage induced by pro-
inflammatory TNF-a (Sabin et al. 2007) and that
EPA would further reduce the lipotoxic and cytotoxic
effect of elevated palmitate plus TNF-a. The present
study was designed to investigate the cellular and
molecular mechanisms of lipotoxic (palmitate) and
cytotoxic (TNF-a) combinations on skeletal muscle
cell survival and differentiation in the absence or
presence of EPA. The ultimate aim was therefore to
improve muscle cell survival and differentiation using
EPA as a myoprotective agent, and elucidate the
underlying mechanisms of action.
Materials & methods
Materials
All cell and tissue culture media and supplements were
purchased as sterile or were filter sterilised through a
0.20 lMfilter. Heat-inactivated (hi) foetal bovine serum
(FBS) and hi new born calf serum (NCS)were purchased
fromGibco (Paisley, Scotland); hi horse serum(HS) from
TCS Biosciences (Corby, England); penstrep (penicillin
and streptomycin) and trypsin from Bio Whittaker
(Wokingham, England); L-glutamine from BDH (Poole,
England), gelatine from Sigma (St. Louis, USA). Glass-
ware, distilled water (dH2O) and phosphate buffered
saline (PBS, Oxoid (Hampshire, England) were auto-
claved prior to use. Sterile media were stored at 4 C and
used within 2 months. Plasticware were purchased as
sterile from Greiner Bio-one, (Kremsmunster, Austria)
unless otherwise stated. EPA purchased from IDS Ltd
(Boldon, Tyne & Wear, UK) and Palmitate (Sigma-
Aldrich, Poole, UK)were complexedwith fatty-acid free
bovine serum albumin (BSA) (Sigma-Aldrich, Poole,
UK). Recombinant human TNF-a was purchased from
Calbiochem (Nottingham, England); TRIZOL reagent
(Invitrogen, Life Technologies), propidium iodide (PI)
stain from BD Biosciences (San Diego, USA) and
creatine kinase assay kits from Catachem (Bridgeport,
USA). Recombinant human IGF-I was purchased from
GroPep (Adelaide, Australia). BCATM protein quantita-
tion reagents were obtained from Pierce Chemicals
(Chester, England, UK).
Cell culture
C2 mouse skeletal myoblasts (passages 8–12) (Yaffe
and Saxel 1977) were grown in T75 flasks in a
humidified 5% CO2 atmosphere at 37 C in growth
medium (GM), composed of: DMEM with Glutamax
supplemented with 10% hiFBS, 10% hiNCS, penstrep
and additional L-glutamine, at final concentrations of
10000 U ml-1 and 2 mM respectively, until 80%
confluency was attained. Experiments and differenti-
ation were initiated following washing with phosphate
buffered saline (PBS), by transferring to low serum-
containing differentiation medium (DM; DMEM plus
glutamax, supplemented with 2% HS, penstrep and
additional L-glutamine (supplemented as above)) in
the absence or presence of specific cytokines, growth
factors, lipids and signal inhibitors described below.
C2 myoblasts, upon serum withdrawal, are able to
undergo spontaneous differentiation into myotubes
and do not require growth factor addition to stimulate
the process (Florini et al. 1991). Adherent cells
following trypsinisation, and detached cells in the
supernatant, were counted using a haemocytometer in
the presence of trypan blue dye (Bio Whittaker,
Wokingham, England) to assess viability and cell
number.
Cell treatments
Six-well plates were pre-coated with 0.2% gelatin
(Sigma) for 5 min at room temperature. Following
removal of excess gelatin, cells were seeded at
1 9 105 cells ml-1 in GM. On attaining 80% conflu-
ency, cells were washed twice with PBS and trans-
ferred to DM for 30 min at 37 C. The end of this
30 min equilibration time-point was denoted time 0.
Interactions of FFAs with TNF-a and IGF-I
To evaluate the effects of FFAs on myoblast death and
myogenic differentiation, DM supplemented with
EPA (50 lM) (Magee et al. 2008) or Palmitate
(750 lM) (Sabin et al. 2007) was added to cell
cultures at time-point 0 for 1-h pre-incubation prior to
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vehicle, TNF-a and/or IGF-I addition (doses described
below). EPA was first complexed with fatty-acid free
BSA. Briefly, EPA stock solutions (50 mM) were
prepared in absolute ethanol and stored at-20 C in a
glass vial in the dark. Working solutions were
prepared by adding the required volume of EPA stock
solution to pre-warmed (37 C) DMEM containing
4% (w/v) fatty acid-free BSA. Dilutions were main-
tained at 37 C for at least 1-h before their addition to
cell cultures. The final concentration of ethanol in
cultures was below 0.1%. Medium containing palmi-
tate was generated based on a previously published
method (Schmitz-Peiffer et al. 1999). Briefly, FFA-
depleted albumin was dissolved in serum free media
(SFM) to make a 20% albumin solution. 75 mM
palmitate in ethanol was mixed with the albumin
solution and made up with 2% media to generate a
final FFA-containing media with 5% albumin. Serial
dilutions were performed, prior to adding 2% HS
containing media in order to maintain the final
albumin concentration at 5%. Final solutions were
filter-sterilised before use. Doses of palmitate were
based on previously published studies on our data in
human skeletal muscle cells and of others in C2C12
cells (Sabin et al. 2007; Schmitz-Peiffer et al. 1999).
Control wells were dosed with media containing 5%
albumin and no FFAs. The pH of the media did not
differ significantly with the addition of the complexed
fatty acid. EPA and palmitate were delivered 30-min
following change to DM. Where EPA and palmitate
were co-incubated, both were simultaneously admin-
istered. On cytokine and growth factor interactions at
time-point 1-h after EPA and/or Palmitate treatment,
myoblasts received TNF-a (1.25 or 10 ng ml-1), IGF-
I (1.5 ng ml-1) or TNF-a (10 ng ml-1) ? IGF-I
(1.5 ng ml-1). Following 36 and 72 h incubations,
RNA was extracted for real time RT-PCR. For cell
counting and flow cytometric studies, cells were
trypsinised 48 h following dosing. For studies involv-
ing creatine kinase assays, cells were harvested
following 72 h incubation, as described below.
TNF-a and IGF-I inhibitor studies
Where inhibitor studies were performed, upon reaching
80% confluency, cells were washed twice in PBS and
were immediately transferred into DM. After 30-min,
wells were treated in the absence or presence of the
MEK inhibitor, PD98059 (20 lM) (Al-Shanti et al.
2008; Saini et al. 2008, 2010, 2012, ) or in the absence of
presence of fungal toxin fumonisin B1 (FB1) (an
inhibitor of ceramide synthase (20 lM)) as previously
demonstrated (Mebarek et al. 2007). After 1-h myo-
blasts were administered with EPA and/or Palmitate for
1-h at 37 C. Cultures were subsequently spiked with
TNF-a (1.25 or 10 ng ml-1) or IGF-I (1.5 ng ml-1) or
TNF-a (10 ng ml-1) ? IGF-I (1.5 ng ml-1).
Primer design and synthesis
Optimal primer designs are essential to ensure that
only a single PCR product is amplified using quanti-
tative Real Time PCR based SYBR Green technology,
Web-based software from Invitrogen was used to
design primers (Table 1) which were further analysed
by Sigma- Genosys software. The primers were
designed to yield products spanning exon–exon
boundaries to prevent possible genomic DNA-con-
tamination. Sequence homology searches against the
database of GenBank showed that these primers
matched only the sequence against which they were
designed. Primers were synthesised by Sigma-
Genosys (Suffolk, UK) which are compatible with
real-time PCR without further purification.
RNA extraction and qRT-PCR
Following cell treatments and incubations, differenti-
ation medium was aspirated, cells were washed with
PBS and lysed with 200 ll TRIZOL reagent. RNA
was extracted from TRIZOL homogenates according
to the manufacturer’s instructions (Invitrogen, CA,
USA). Thirty ng RNA was used per reaction. Follow-
ing RNA isolation, qRT-PCR was performed with the
Chromo4 Detection System (Biorad Laboratories,
Hercules, CA, USA), supported by Opticon Monitor
Version 3.1 analysis software and using Biorad
iScriptTM One-Step RT-PCR Kit with SYBR Green,
(Hercules, CA, USA) according to the manufacturers’
instructions. The amplification program included an
initial denaturation step at 95 C for 10 min, followed
by 40 cycles of denaturation at 95 C for 15 s, and
annealing and extension at 60 C for 1 min. SYBR
Green fluorescence was measured after each extension
step, and the specificity of amplification was evaluated
by melting curve analyses. The relative gene expres-
sion levels were calculated using the comparative Ct
(DDCt) method (Schmittgen and Livak 2008), where
Biogerontology
123
the relative expression is calculated as 2-DDCt and
where Ct represents the threshold cycle. The calibrator
condition for 2-DDCt calculation was DM control at
36 h. The reference gene was RP-IIb/Polr2b) Table 1,
and was stable (Ct value mean ± SD = 24.482 ±
0.59) across experimental conditions. Every sample
was run in three separate experiments in duplicate.
Analysis of cell cycle by flow cytometry
Following 48 h incubation, adherent cells were trypsi-
nised in 0.2 ml of 0.5% trypsin/0.02% EDTA solution
and were pooled with detached cells, resuspended and
washed inPBSprior to fixing at-20 C in70%ethanol.
After a minimum of 24-h, cells were pelleted
(2009g for 5-min), washed in PBS (three times
2009g for 5-min) and resuspended with gentle vortex-
ing in propidium iodide labelling buffer (50 lg ml-1
propidium iodide, 0.1% sodium citrate, 20 lg ml-1
ribonuclease A, 0.3% Nonidet P-40, pH 8.3) at approx-
imately *1 9 106 cells ml-1. Cells were stored in the
dark at 4 C for 30-min, prior to assaying at room
temperature, using a Becton–Dickinson FACSCalibur
flow cytometer. Data were analysed using Cell Quest
software (Becton–Dickinson, Oxford, England).
Analysis of intracellular caspase detection by flow
cytometry
Following 48 h incubation, myoblasts were stained
directly by adding 10 ml of ApoStat (R & D Systems,
Abingdon, UK) per 1 ml culture volume at 37 C.
After the staining period, cells were harvested into
5 ml tubes, centrifuged at 5009g for 5 min and
washed once with 4 ml PBS to remove unbound
reagent. Cells were resuspended in 500 ll of PBS for
flow cytometric analyses. Induced and non-induced
cells were observed on a side scatter versus forward
scatter linear dot plot to identify and gate cells of
interest. Fluorescein detection was collected on the
FL1 channel (employing an argon laser at 488 nm).
Flow cytometry: cytometric bead array (CBA)
for quantification of phosphorylated proteins
BDTM CBA is a flow cytometry application based on
phycoerythrin (PE) antibody-coated beads for simul-
taneous quantification of multiple proteins, including
intracellular phosphorylated signalling proteins
(Schubert et al. 2009) in single samples. Cells were
washed at 4 C in PBS and lysed using 1 9 lysis
buffer provided in the Cell Signalling Master Buffer
Kit (BDTM CBA). The cell lysates were denatured at
100 C and dispersed using a 26- gauge needle. A
protein assay (BCATM) was performed to determine
protein concentrations of individual samples. Cell
lysates were stored at -70 C until required for the
CBA. Samples were thawed and added to the assay
diluent provided in the Cell Signalling Master Buffer
Kit (15 lg/sample). Standards were prepared using a
stock of recombinant protein (50,000 U ml-1) con-
tained in the BDTM CBA Cell Signalling Flex Set
Table 1 Primer sequences
Target gene Primer sequence (50–30) Ref. seq
number
Primer length (product length) bp
IGF-II F: TCTCATCTCTTTGGCCTTCG
R: AAGCAGCACTCTTCCACGAT








NM_010518 20 (product length 193)
20
RP-IIb (polr2b) F: GGTCAGAAGGGAACTTGTGGTAT
R: GCATCATTAAATGGAGTAGCGTC










(JNK). Serial dilutions of the top standard (1000 U
ml-1) were performed. All samples were incubated in
the dark for 2 h prior to further investigation. PE
detection reagent was added to each sample and
incubated at RT (protected from light) for a further
1 h. The samples were washed in wash buffer
(provided in CBA kits) and centrifuged at 3009g for
5 min. Excess liquid was removed and 300 ll fresh
wash buffer was added to each pelleted sample, prior
to gentle vortexing and analyses using Cell Quest Pro
(Becton–Dickinson) on a BDTM FACS Calibur as per
manufacturer instructions. Data were uploaded from
Cell Quest Pro, filtered using FCS FilterTM and
analysed using FCAP array software (Hungary Soft-
ware Ltd., for BD Biosciences).
Creatine kinase assay
Cells were treated as described above, washed twice
with PBS and lysed in 0.2 ml of 50 mMTris-MES, pH
7.8, 1% Triton X-100 (TMT buffer). Samples were
stored at -80 C, and assayed within 2 weeks of
harvesting using a commercially available kit (Cat-
achem CK assay) according to manufacturer’s instruc-
tions. Enzymatic activity was normalised to total
protein content as determined by the BCATM assay
(Pierce, Rockford, IL, USA).
Statistical analysis
Data were analysed using Microsoft Excel version 7.0
and SPSS version 11.5 software and GraphPad version
5.0 software. Results are presented as the mean ± s-
tandard error of the mean (SEM). Statistical signifi-
cance was determined using one-way analysis of
variance with multiple post hoc analyses. Results were
considered statistically significant when P\ 0.05. All
experiments were performed at least 3 times in
duplicate, unless otherwise stated.
Results
Palmitate increases cell death and reduces
differentiation, which is improved with EPA
administration
Initial experiments assessed the effects of EPA
(50 lM) and palmitate (750 lM) on C2 skeletal
muscle cells. Basal myoblast death was the same in
control DM-treated and EPA-treated cells, whereas
increased levels of death were evident following
palmitate administration (Fig. 1a). At a microscopic
level, this increase in cell death with palmitate
appeared to be reduced by a co-incubation with EPA
(Fig. 1a, bottom panel). Wishing to substantiate these
morphological findings, apoptotic cell death was
assessed using FLOW cytometry (Fig. 1b). Data
confirmed basal cell death (pre-G1 phase cells) in
the presence of DM (5.6 ± 0.7%), which was unal-
tered by pre-treatment with EPA (5.5 ± 0.6%;
p = N.S.; Fig. 1b). By contrast, cell death was
significantly increased (vs. DM and EPA) by a single
dose of palmitate (22 ± 0.9%; P\ 0.05; Fig. 1b,
indicated by *). However, in contrast to the morpho-
logical data, analysis of pre G1 fragmentation by flow
cytometry illustrated that when palmitate was co-
incubated with EPA, there was only a small non-
significant reduction in cell death versus palmitate
alone (19 ± 0.9 vs. 22 ± 0.9%; Fig. 1b).
Having monitored the effect of EPA and palmitate
on cell death, we next investigated their impact on
muscle cell differentiation. We hypothesised EPA
would have little effect and palmitate would reduce
differentiation versus DM control. Creatine kinase
activity, a biochemical marker of myoblast differen-
tiation, was elevated after 72 h in control samples
(562 ± 16 units mg ml-1; Fig. 1c). Myotube forma-
tion was also observed in myoblasts receiving EPA,
which displayed maximal creatine kinase activity
(817 ± 17 units mg ml-1) and was significantly
higher (P\ 0.05) versus DM alone (Fig. 1c). In
myoblasts treated with palmitate, creatine kinase
activity was reduced versus control DM and EPA
alone (68 ± 19 units mg ml-1; P\ 0.05 vs. DM and
vs. EPA, Fig. 1c, indicated by ?). Co-incubating
palmitate and EPA resulted in significantly elevated
creatine kinase activity compared to palmitate alone
(P\ 0.05) increasing to 325 ± 16 units mg ml-1,
Fig. 1c, indicated by #), suggesting EPA not only
enabled differentiation basally, but was capable of
partially rescuing the inhibitory impact of palmitate on
differentiation.
To further understand the regulation of myotube
formation, the gene expression profiles of key myo-
genic markers were analysed (Fig. 1d). Importantly,
IGF-II, IGFBP-5, MyoD and myogenin expression
(Fig. 1d) were all up-regulated at 72 h in response to
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DM treatment. Since EPA increased biochemical
differentiation, it was subsequently hypothesised that
expression of these modulators of differentiation
would also be increased under these culture condi-
tions. Indeed, EPA resulted in higher gene expression
relative to DM for IGF-II (2.13 ± 0.18 vs. 1.56 ± 0.1
e; P\ 0.05, Fig. 1di indicated by *) and MyoD
(2.13 ± 0.21 vs. 1.31 ± 0.11; P\ 0.05; Fig. 1dii,
indicated by *). By contrast, there was no difference in
Myogenin (2.2 ± 0.16 vs. 1.8 ± 0.13; Fig. 1diii) or
IGFBP-5 (1.48 ± 0.16 vs. 1.5 ± 0.46; Figs. 1div)
expression at 72 h between EPA and DM treated cells.
In line with its ability to suppress differentiation,
palmitate significantly reduced all gene transcripts
associated with differentiation when compared to DM
control at 72 h; IGF-II (0.51 ± 0.07; P\ 0.05),
MyoD (0.16 ± 0.06; P\ 0.05), myogenin (0.13 ±
0.07; P\ 0.05) and IGFBP-5 (0.05 ± 0.005;
Fig. 1 Palmitate increases death and reduces differentiation in
myoblasts, with differentiation improved with EPA administra-
tion. a At a microscopic level, an increase in cell death was
observed with palmitate that appeared reduced by a co-
incubation with EPA. Arrows indicate congregations of dead
cells. b Flow cytometric data confirmed, cell death was
significantly increased (vs. DM and EPA) by a single dose of
palmitate (22 ± 0.9%; indicated by *). With the addition of
EPA there was a reduction in cell death versus palmitate alone
(19 ± 0.9 vs. 22 ± 0.9%) however, significance was not
achieved. c EPA alone significantly increased biochemical
differentiation (creatine kinase (CK) activity) (817 ± 17 vs.
562 ± 16 units mg-1 ml-1 in DM control, indicated by *). With
palmitate, CK activity was significantly reduced versus control
DM and EPA alone (68 ± 19 units mg ml-1; P\ 0.05 vs. DM
and vs. EPA; indicated by ?). Co-incubating palmitate and
EPA, resulted in significantly elevated creatine kinase activity
compared to palmitate alone, increasing to 325 ± 16 units mg
ml-1 (indicated by #). d Gene expression of IGF-II (di), MyoD
(dii), myogenin (diii) and IGFBP5 (div) was up-regulated at
72 h (relative to DM 36 h) in response to differentiation in
control conditions (DM treatment). EPA resulted in higher gene
expression compared with DM for IGF-II (2.13 ± 0.18 vs.
1.56 ± 0.1; di indicated by *) and MyoD (2.13 ± 0.21 vs.
1.31 ± 0.11; P\ 0.05; dii indicated by *). In line with its
ability to suppress differentiation, palmitate significantly
reduced all positive gene transcript regulators of differentiation
at 72 h; IGF-II (0.51 ± 0.07; P\ 0.05), MyoD (0.16 ± 0.06;
P\ 0.05), myogenin (0.13 ± 0.07; P\ 0.05) and IGFBP-5
(0.05 ± 0.005; P\ 0.05) di–iv respectively; indicated by ?,
and significantly increased inhibitor of differentiation 3 (Id3;
dv) expression levels (5.51 ± 1.04) compared with DM
(1.01 ± 0.001; P\ 0.05; indicated by *). Addition of EPA to
palmitate versus palmitate alone elevated IGF-II 1.5 fold
(0.75 ± 0.15 vs. 0.51 ± 0.07; P[ 0.05; di indicated by #),
MyoD 2.2 fold (0.35 ± 0.05 vs. 0.16 ± 0.06; P[ 0.05; dii
indicated by #), Myogenin 3.5 fold (0.45 ± 0.02 vs.
0.13 ± 0.07; P\ 0.05; diii indicated by #) and IGFBP-5 9.2
fold (0.46 ± 0.07 vs. 0.05 ± 0.005; P\ 0.05; div indicated by




P\ 0.05) shown in Fig. 1di–iv respectively; indicated
by ?.
Having observed that EPA was able to partially
rescue the inhibitory effects of palmitate on biochem-
ical differentiation, we next assessed the impact of co-
incubations of these lipids on the molecular regulators
of differentiation. Co-treatment of palmitate with EPA
versus palmitate alone did elevate IGF-II 1.5 fold
(0.75 ± 0.15 vs. 0.51 ± 0.07; P\ 0.05; Fig. 1di;
indicated by #), MyoD 2.2 fold (0.35 ± 0.05 vs.
0.16 ± 0.06; P\ 0.05; Fig. 1dii; indicated by #),
Myogenin 3.5 fold (0.45-fold ± 0.02 vs. 0.13-
fold ± 0.07; P\ 0.05; Fig. 1diii; indicated by #)
and IGFBP-5 9.2 fold (0.46-fold ± 0.07 vs. 0.05-
fold ± 0.005; P\ 0.05; Fig. 1div; indicated by #). It
is important to note, however, that despite these
increases in gene expression with EPA in the presence
of palmitate, levels were not completely restored back
to control DM levels or those of EPA alone. However,
this consolidated the morphological and biochemical
data, where differentiation was improved with EPA in
the presence of lipotoxic palmitate but not returned to
levels in DM control.
Finally, in order to determine whether Id3, an
inhibitor of differentiation, may be involved in
palmitate-induced suppression of differentiation, we
examined its expression. As is evident in Fig. 1dv,
palmitate significantly increased Id3 expression levels
(5.51 ± 1.04) compared with DM (1.01 ± 0.001;
P\ 0.05; indicated by *) or EPA alone
(0.64 ± 0.06; P\ 0.05). Interestingly, when EPA
was co-incubated with palmitate, there was no change
in expression levels compared with palmitate alone,
suggesting that rescue of differentiation by EPA does
not involve suppression of Id3.
Caspases increase with palmitate and are reduced
with EPA
To determine whether caspase activation was involved
in palmitate-induced apoptosis, myoblasts were trea-
ted with a cell-permeable, FITC-conjugated, pan-
caspase inhibitor (ApoStat) and increased fluores-
cence associated with increased caspase activity was
quantified by FLOW cytometry (Fig. 2). Data illus-
trated that under control and EPA alone conditions,
caspase activity was at baseline (7 ± 2% and 9 ± 3%
respectively), consistent with the pre-G1 FLOW
cytometric data described above. However, the addi-
tion of palmitate to the cells significantly (P\ 0.05)
increased the percentage of caspase active events
(38 ± 8%) (Fig. 2a, indicated by *) initially suggest-
ing palmitate may induce apoptosis via caspase-
mediated mechanisms. Co-incubation of EPA and
palmitate lowered caspase activity to 24 ± 4%
(P\ 0.05, Fig. 2a indicated by ?). This reduction in
caspase activation with EPA addition however, was in
contrast to the non-significant reduction of palmitate-
induced DNA fragmentation observed above
(Fig. 1b).
Since caspase activity was elevated in the presence
of palmitate, we wished to discover whether inhibiting
caspases would reduce rates of myoblast death. We
have previously demonstrated in C2 myoblasts, using
western blotting and caspase activity assays that
caspase-8 is activated under myotoxic (cytotoxic)
stress (Stewart et al. 2004). Addition of ZIETD-FMK
(caspase 8 inhibitor) in addition to Z-VDVAD-FMK
(caspase-2 inhibitor) and Z-DEVD-FMK (caspase-3
inhibitor), (Fig. 2b) only partially reduced the inci-
dence of myoblast death in the presence of palmitate,
suggesting a cumulative/alternative compensatory
role for these enzymes in palmitate-induced inhibition
of differentiation and induction of cell death.
MAPK inhibition reduces palmitate induced cell
death
Having demonstrated that caspases are activated in the
presence of palmitate, but that individual caspase
inhibition does not independently rescue the effects of
palmitate, we wished to investigate what other
signalling pathways may be involved in the cell death
effects of palmitate. We initially monitored the
potential role of the MAPKs (Fig. 3a, b) in palmi-
tate-induced apoptosis. Morphological data showed
clearly that palmitate-induced cell death was reduced
in the presence ofMAPK inhibition (Fig. 3a).Wishing
to substantiate these findings, we performed FLOW
cytometric quantification of fragmented DNA and
report here that the increase in apoptosis induced by
palmitate (22 ± 1%; Fig. 3b, indicated by *) was
significantly reduced by a co-incubation with 20 lM
PD98059 (MEK inhibitor) (13.5 ± 1.2%; P\ 0.05;
Fig. 3b, indicated by ?), confirming the morpholog-
ical data in Fig. 3a. These data suggest that MAPK
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activation may contribute to palmitate-induced
apoptosis.
Effects of palmitate plus EPA in the presence
of TNF-a and IGF-I on skeletal myoblast death
and differentiation
Having established a potential beneficial role of EPA
against palmitate-induced reductions in differentia-
tion, we next wished to test the specificity of this
finding. We have previously shown (Foulstone et al.
2004; Saini et al. 2008) and demonstrate again here
(Fig. 4a) that TNF-a induces dose responsive apop-
totic cell death in C2 skeletal myoblasts, with the
greatest induction of cell death apparent following
administration of 10 ng ml-1 TNF-a (22 ± 0.5%;
P\ 0.05). Critically, the capacity of the cells to
differentiate and to form myotubes was also blocked
(P\ 0.05) at both doses of TNF-a tested, even that
which did not induce apoptosis (1.25 ng ml-1;
Fig. 4ai). With IGF-I addition (1.5 ng ml-1) we were
able to reduce the apoptotic effect of high dose TNF-a
(10 ng ml-1) from 22 ± 0.5 to 12 ± 0.8%; P\ 0.05,
Fig. 4a, indicated by u.
Pre-treatment with EPA (50 lM) or palmitate
(750 lM) induced opposing effects upon TNF-a
induced myoblast death. Addition of EPA to high
dose TNF-a (10 ng ml-1) significantly lowered the
incidence of death (22 ± 0.5 to 15 ± 0.7% TNF-a vs.
TNF-a ? EPA; P\ 0.05; Fig. 4a, indicated by #). In
contrast, palmitate addition increased myoblast death
under all conditions (Fig. 4a, indicated by *). As
already demonstrated and confirmed here, palmitate
elicited a significant increase in cell death compared to
Fig. 2 Caspases increase with palmitate and are reduced with
EPA, but do not seem to be sole regulators of palmitate-induced
death. a In control and EPA conditions, caspase activity was at
baseline (7 ± 2 and 9 ± 3% respectively). The addition of
palmitate to the cells significantly (P\ 0.05) increased the
percentage of caspase active events (38 ± 8%) (a indicated by
*). Co-incubation of EPA and palmitate lowered caspase
activity to 24 ± 4% (P\ 0.05, a indicated by ?). b Addition
of caspase inhibitors; Z-VDVAD-FMK (caspase-2), Z-DEVD-
FMK (caspasase- 3) and ZIETD-KMK (caspase 8) (b) only
partially reduced the incidence of myoblast death in the
presence of palmitate. Data are presented as Mean ± SEM
(n = 3, in duplicate for each group)
Fig. 3 MAPK inhibition reduces Palmitate induced cell death.
a Morphological data show that palmitate-induced death was
reduced in the presence of MAPK inhibition. Arrows indicate
congregations of dead cells. b Flow cytometric quantification of
fragmented DNA also showed that palmitate induced apoptosis
(22 ± 1%; b indicated by *) that was significantly reduced by
co-incubation with 20 lM PD98059 (MEK inhibitor)
(13.5 ± 1.2%; P\ 0.05; b indicated by ?). Data are presented
as Mean ± SEM (n = 3, in duplicate for each group)
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DM (5.6 ± 0.7 to 22 ± 0.9% DM vs. palmitate,
P\ 0.05, indicated by *a). Addition of palmitate to
high dose TNF-a alone (10 ng ml-1) acted to further
the incidence of cell death, elevating from 22 ± 0.5%
in TNF-a alone to 46.6 ± 2.8% TNF-a ? palmitate
(P\ 0.05, Fig. 4, indicated by *b). Since palmitate
induced a significant increase in cell death and EPA
protected myoblasts from the effects of high dose
TNF-a (10 ng ml-1) we wished to determine whether
EPA could rescue the detrimental impact of palmitate
co-administration with high dose TNF-a (10 ng
ml-1). Addition of EPA was able to lower the
induction of death in the presence of palmitate plus
TNF-a from 46.6 ± 2.8 to 39.5 ± 3% (P\ 0.05,
Fig. 4a, indicated by ?).
Having determined that EPA was able to elicit a
significant effect on the cell death inducing abilities of
palmitate plus TNF-a, we next wished to investigate
the impact of these co-incubations on myoblast
differentiation. As previously demonstrated (Fig. 1c),
EPAwas able to increase basal differentiation and also
partially rescue the negative impact of palmitate on
CK activity (Fig. 4b). EPA administration was unable
to rescue the block of differentiation in myoblasts
administered with TNF-a (1.25 or 10 ng ml-1).
Palmitate (750 lM) significantly (P\ 0.05) lowered
CK activity under all treatment regimens (Fig. 4,
indicated by *). Administration with EPA in the
presence of palmitate only partially rescued the block
of differentiation, but critically, in the presence of
TNF-a (regardless of the treatment regime), EPA
bFig. 4 Effects of an interaction between Palmitate and EPA in
the presence of TNF-a and IGF-I on skeletal myoblast death and
differentiation. aApoptosis: TNF-a induced apoptotic cell death
in a dose dependent manner and the capacity of cells to
differentiate and form myotubes was also blocked (P\ 0.05) at
all doses of TNF-a, as suggested previously (Foulstone et al.
2004; Saini et al. 2008; Sharples et al. 2010). With IGF-I
addition (1.5 ng ml-1) we were able to reduce the apoptotic
effect of high dose TNF-a (10 ng ml-1) from 22 ± 0.5 to
12 ± 0.8%; P\ 0.05, a indicated by u. Addition of EPA
(50 lM) to high dose TNF-a (10 ng ml-1) significantly lowered
the incidence of death (22 ± 0.5 to 15 ± 0.7% TNF-a vs. TNF-
a/EPA; P\ 0.05; a indicated by #). In contrast, palmitate
addition increased myoblast death under all conditions (a indi-
cated by *). As already demonstrated and confirmed here,
palmitate elicited a significant increase in cell death compared to
DM (5.6 ± 0.7 to 22 ± 0.9% DM vs. palmitate, P\ 0.05,
indicated by * a). Addition of palmitate to high dose TNF-a
alone (10 ng ml-1) acted to further the incidence of death,
elevating from 22 ± 0.5% in TNF-a alone to 46.6 ± 2.8%
TNF-a ? palmitate (P\ 0.05; a indicated by * b). Addition of
EPA lowered the induction of death in the presence of palmitate
plus TNF-a alone from 46.6 ± 2.8 to 39.5 ± 3% (P\ 0.05; a
indicated by ?). b CK activity/differentiation: As previously
demonstrated (Fig. 1c), EPA was able to somewhat rescue the
negative impact of palmitate on CK activity. However, EPA
administration was unable to rescue the block of differentiation
in myoblasts administered with TNF-a (1.25 or 10 ng ml-1).
Palmitate (750 lM) significantly (P\ 0.05) lowered the rates
of CK activity under all treatment regimens ( indicated by *).
Administration with EPA in the presence of palmitate could not
restore the block of differentiation, but critically, in the presence
of TNF-a (regardless of the treatment regime), EPA returned
CK activity levels to those seen in the complete absence of
palmitate e.g. it negated the interaction of palmitate plus TNF-a
on differentiation (b indicated by ?). Data are presented as
Mean ± SEM (n = 3, in duplicate for each group)
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returned CK activity levels to those seen in the
complete absence of palmitate e.g. it negated the
interaction of palmitate with TNF-a on differentiation
(Fig. 4b, indicated by ?). This is different to the
outcome seen with apoptosis (Fig. 4a), where cell
death levels in the presence of EPA did not reduce to
trigger levels in the absence of palmitate, suggesting
EPA is more potent at protecting against palmitate or
palmitate/TNF-a induced block on differentiation
rather than the induction of cell death.
EPA enables a partial rescue of IGF-II, IGFBP-5,
MyoD, myogenin and Id3 expression
in the presence of both TNF-a and palmitate
IGF-II (Fig. 5ai, aii), IGFBP-5 (Fig. 5b), MyoD
(Fig. 5c) and myogenin (Fig. 5d) expression were all
down-regulated, relative to control conditions in the
presence of TNF-a (indicated by u). By contrast, Id3
expression was significantly increased in myoblasts
receiving high dose TNF-a (10 ng ml-1) 3.6 ± 0.99 at
72-h (P\ 0.05) relative to DM (Fig. 5e, indicated by
u). Addition of EPA (50 lM) induced significant
(P\ 0.05) increases in expression of IGF-II vs. DM
alone; 2.2 ± 0.2 vs. 1.5 ± 0.1 (Fig. 5ai, indicated by
*). Pre-administration with palmitate (750 lM) signif-
icantly (P\ 0.05) reduced expression of IGF-II across
the dose range with exception of low dose TNF-a
(Fig. 5ai, indicated by ?). Critically, the greatest
decline in IGF-II expression in the presence of palmitate
was in myoblasts administered with IGF-I (1.5 ng
ml-1) alone where an 87 ± 7% decrease in expression
was observed (P\ 0.05), suggesting palmitate is
capable of preventing the beneficial impact of exoge-
nous IGF-I on endogenous IGF-II production (Fig. 5ai,
indicated by #). As previously suggested, simultaneous
co-incubation of EPA (50 lM) with palmitate
(750 lM) was able to ameliorate some of the negative
effects of palmitate alone on IGF-II expression
(Fig. 5aii, indicated by *), in particular those decreases
associated with high TNF-a plus palmitate, where the
addition of EPA returned IGF-II expression to DM
control values in the presence of palmitate alone
(Fig. 5aii indicated by no significant differences i.e.
P[ 0.05).
Similar profiles were observed for IGFBP-5
(Fig. 5b), MyoD (Fig. 5c) and Myogenin (Fig. 5d)
expression. Addition of palmitate to myoblasts signif-
icantly reduced IGFBP-5 expression across all
treatments of TNF/IGF administration (to 0.034 ±
0.008 on average across all treatment groups, Fig. 5b,
indicated by *). With co-incubation of EPA, IGFBP-5
levels increased significantly to 0.36 ± 0.057 (Fig. 5b,
indicated by ?) relative to control. For MyoD expres-
sion (Fig. 5c), palmitate addition lowered levels to
0.17 ± 0.06 on average (Fig. 5c, indicated by *) and
co-incubation with EPA increased levels to
0.404 ± 0.046 relative to control conditions and
resulting in increases versus palmitate alone conditions
(Fig. 5c). Formyogenin expression (Fig. 5d) palmitate
addition lowered levels to 0.19 ± 0.04 on average
(Fig. 5d, indicated by *) but co-incubation with EPA
increased levels to 0.37 ± 0.025 relative to control
resulting in increased expression versus palmitate
alone conditions (Fig. 5d). However, these were still
below control conditions in the presence of DM alone
suggesting a partial recovery only above palmitate
alone, yet not restoring back to baseline control levels.
The addition of EPA significantly reduced Id3
expression relative to high dose TNF-a (10 ng ml-1)
(from 3.6 ± 0.99 to 0.55 ± 0.068 in TNF-a vs. TNF-
a/EPA, respectively, Fig. 5e, indicated by #) suggest-
ing EPA may stimulate differentiation by increasing
expression of myogenic markers for differentiation,
while simultaneously lowering expression of inhibi-
tors of differentiation. With palmitate administration
Id3 expression was greatly elevated relative to
matched-controls and peaked with high dose TNF-a
alone (22 ± 1.5, Fig. 5e, indicated by *). Co- incu-
bation of EPA with palmitate resulted in a decrease in
Id3 expression across the dose range and this was
significant (P\ 0.05) for low (1.25 ng ml-1) and high
dose TNF-a (10 ng ml-1) (Fig. 5e indicated by ?).
MAPK inhibition reduces cell death in palmitate
combined with elevated TNF-a conditions
Having demonstrated that MAP Kinase activation was
important for the induction of cell death in the
presence of TNF-a or palmitate alone, we next wished
to investigate whether MAP Kinases underpinned the
enhanced apoptotic potential of palmitate combined
with TNF-a. Morphological data showed clearly that
MAPK inhibition reduced the number of detached
cells (Fig. 6a) and this reduction resulted in a decrease
in the level of apoptosis (Fig. 6b). As shown above,
when compared with controls, apoptosis was
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significantly elevated across the treatment conditions
in the presence of palmitate alone, low dose and high
dose TNF-a. Inhibition of MEKK signaling with
PD98059 (20 lM) was effective in lowering rates of
cell death observed in palmitate conditions to levels
comparable to control conditions, where basal cell
Fig. 5 EPA enables a partial rescue of IGF-II, IGFBP-5,
MyoD, myogenin and Id3 expression in the presence of both
palmitate and TNF-a combined. IGF-II (ai, ii) IGFBP-5
(b) MyoD (c) and myogenin (d) expression was reduced,
relative to control conditions in the presence of TNF-a across
the dose range (highlighted by u with high TNF-a 10 ng ml-1).
In contrast, Id3 expression was significantly increased in
myoblasts receiving high dose TNF-a relative to DM
(P\ 0.05, e indicated by u). Addition of EPA (50 lM) induced
significant (P\ 0.05) increases in expression of IGF-II vs. DM
alone (ai, indicated by *). Pre-administration with palmitate
(750 lM) significantly (P\ 0.05) reduced expression of IGF-II
with TNF-a administration (ai, indicated by ?). A decrease in
IGF-II expression in the presence of palmitate plus IGF-I
(1.5 ng ml-1) was also observed (P\ 0.05; ai, indicated by #).
Simultaneous co-incubation of EPA with palmitate (750 lM)
was able to ameliorate some of the negative effects of palmitate
alone (aii, indicated by *), in particular those decreases
associated with high TNF-a, where levels were returned to
control values in the presence of palmitate (aii indicated by no
significant differences between high TNF-a conditions and DM
i.e. P[ 0.05). Addition of palmitate to myoblasts significantly
reduced IGFBP-5, myoD and myogenin gene expression versus
control (b–d respectively indicated by *). Co-incubation with
EPA increased levels of these genes relative to palmitate alone
(resulting in significant increases in IGFBP5, b indicated by?).
These were however, still below control conditions in the
presence of DM alone suggesting a partial recovery. The
addition of EPA significantly reduced Id3 expression relative to
high dose TNF-a (e indicated by #). With palmitate adminis-
tration Id3 expression was greatly elevated relative to controls
and peaked with high dose TNF-a alone (e indicated by *). Co-
incubation of EPA with palmitate resulted in a decrease in Id3
expression for low (1.25 ng ml-1) and high dose TNF-a (10 ng
ml-1) (P\ 0.05, e indicated by ?). Data are presented as
Mean ± SEM (n = 3, in duplicate for each group)
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death following MAPK inhibition averaged 13 ± 3%
for DM, low dose TNF-a and IGF-I alone. Interest-
ingly, in conditions associated with highest apoptotic
death, TNF-a (10 ng ml-1) plus palmitate, apoptosis
was reduced from 47 ± 6 to 28 ± 2% (P\ 0.05)
following inhibition of MAPK activity via PD98059
administration (Fig. 6a, b indicated by *).
Ceramide inhibition reduces cell death in palmitate
plus TNF-a conditions via JNK signaling
Finally, we also wished to discover the potential
involvement of ceramide, one of the members of the
sphingomyelin family and an important component
of the lipid bilayer. Ceramide has been reported to
be increased following palmitate administration
(Listenberger et al. 2001), with TNF-a also regulat-
ing its production and controlling its downstream
signaling (De Larichaudy et al. 2012) via the MAP
kinases to induce apoptosis (Stewart et al. 1999a, b).
FumonisinB1 (FB1; 20 lM), which blocks ceramide
synthase and thereby ceramide accumulation, was
added in the absence or presence of palmitate and/or
high dose TNF-a (10 ng ml-1). Furthermore, since
JNK signaling is linked to ceramide activity and
apoptosis we also measured JNK activity using
cytometric bead array technology. The objective was
to discover if ceramide and/or JNK were central to
the role of palmitate/TNF-a induced myoblast death
using an inhibitor that was specific to the sphin-
gomyelin pathway (N.B. at 20 lM FB1 does not
inhibit known protein phosphatases).
Pre-administration of FB1 (20 lM) appeared effec-
tive at reducing the incidence of myoblast death
induced by palmitate (Fig. 7a, indicated by *), where
cell death was still significantly below counterparts
administered with palmitate alone in the absence of
FB1 (Fig. 7a; P\ 0.05 for all treatments, indicated by
*). Maximal apoptotic death with high dose palmitate
plus TNF-a (10 ng ml-1) alone was lowered from
47 ± 6% in palmitate alone conditions to 32 ± 2%
when FB1 was administered in the presence of
palmitate.
Finally, we specifically looked at the effect that this
inhibitor had on JNK activity in treatments that
induced maximal cell death, palmitate with high dose
TNF-a 10 ng ml-1 (Fig. 7b, c). In control conditions
basal JNK activity with DM control treatment at 2- and
24-h was approximately 20 ± 1 units ml-1 (Fig. 7b, c,
indicated by *). This was elevated with high dose
TNF-a administration with levels being significantly
greater (P\ 0.05) at 24-h (72 ± 4 units ml-1, Fig. 7c,
indicated by *) compared with 2-h (41.5 ± 2.5 units
ml-1, Fig. 7b, indicated by *). Following pre-treat-
ment with palmitate, a significant (P\ 0.05) elevation
in JNK activity was observed, even under basal
conditions (79.5 ± 9.5 units ml-1, Fig. 7b, indicated
by ?a at 2-h and 119.5 ± 2.5 units ml-1 at 24-h,
Fig. 7c, indicated by ?a), suggesting palmitate alone
induces JNK activation. JNK activity continued to rise
to 24-h and maximal levels were reported with high
dose TNF-a plus palmitate at 256 ± 10 units ml-1
(Fig. 7c, indicated by ?b). Following co-treatment of
palmitate with FB1 a decrease in JNK activity was
observed across the conditions with levels returning to
basal in myoblasts incubated in DM alone, *17 ± 1
units ml-1 (Fig. 8b, c, indicated by #a). With condi-
tions that induced maximal apoptotic death high TNF-
a and co-treatment of palmitate, incubation with FB1
lowered rates of cell death and this was mirrored by
significant reductions in JNK activity both at 2-h
(Fig. 7b, indicated by #b) and 24-h (Fig. 7c, indicated
by #b) back to those of basal levels. Most notably at
24-h FB1 decreased JNK activity by 66 ± 7% in high
dose TNF-a conditions in the presence of palmitate.
Discussion
In older individuals, age-related changes in body
composition, as well as the increased prevalence of
obesity, determine a combination of excess weight and
reduced muscle mass or strength, recently defined as
sarcopenic obesity (SO). Circulating FFAs and pro-
inflammatory cytokines are elevated and potentially
represent a causal link between obesity and muscle
wasting. Palmitate (saturated FFA) is associated with
reduced IGF signalling—a key pathway in skeletal
muscle differentiation whereas eicosapentaenoic acid
(EPA) a-3 polyunsaturated fatty acid with demonstra-
ble anti-inflammatory activities may have potential
benefits with regards to atrophic skeletal muscle
conditions. Terminally differentiated myofibres are
incapable of division (Saini et al. 2009). Following
damage mononucleated stem cells proliferate, differ-
entiate and enable repair (Saini et al. 2009). We have
investigated the effects of palmitate and EPA on
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differentiating muscle using undifferentiated murine
C2 myoblasts. Additionally, the effect of these FFAs
on cell death or regeneration was investigated in cell
models, previously shown to block differentiation
using low and high level cytokine stress e.g. TNF (1.25
and 10 ng ml-1) and to induce cell death (10 ng ml-1
TNF). The effects of these particular FFAs on muscle
cells have previously been shown to have either
adverse or therapeutic effects, respectively (Magee
et al. 2008; Sabin et al. 2007). In vitro studies have
demonstrated that palmitate reduces insulin-stimu-
lated phosphorylation of AKT (pAKT) (Sabin et al.
2007)—a key downstream signalling molecule in the
IGF system which acts potently to regulate protein
synthesis, skeletal muscle regeneration and differen-
tiation (Glass 2003) whereas EPA is able to reduce
TNF-a-mediated loss of myosin heavy chain expres-
sion and increase myogenic fusion (Magee et al.
2008), although the downstream mechanisms
remained to be defined.
Impact of FFAs, TNF-a and IGF-I on skeletal
muscle cell death and differentiation
In the present study, palmitate (750 lM) was associ-
ated with an increase in apoptosis and inhibition of
Fig. 6 MAPK inhibition reduces cell death in palmitate
combined with elevated TNF-a conditions. a Morphological
data showed that MAPK inhibition reduced the number of
detached cells in the presence of palmitate alone and in
combination with TNF-a (note DM images are the same as
Fig. 3a to enable a comparison with the new dosing conditions).
Arrows indicate congregations of dead cells. bMAPK inhibition
resulted in significant decreases in the level of apoptosis across
the dose range of TNF-a (b indicated by *). Conditions
associated with highest apoptotic death TNF-a (10 ng ml-1)
plus palmitate were reduced from 47 ± 6 to 28 ± 2%
(P\ 0.05) with inhibition of MAPK’s via PD98059 20 lM.




Fig. 7 Ceramide inhibition reduces cell death with palmitate
and TNF-a via JNK signaling. aAdministration of FB1 (20 lM)
was effective at reducing the incidence of myoblast death
induced by palmitate (a indicated by *) across the dose range for
TNF-a. Maximal apoptotic death with high dose palmitate plus
TNF-a (10 ng ml-1) alone was lowered from 47 ± 6 to
32 ± 2% by a pre-incubation with FB1. b, c JNK activity in
the absence or presence of palmitate plus/minus TNF-a at 2-h
b and 24-h c. JNK activity was significantly elevated with high
dose TNF-a administration at 2-h (P\ 0.05, 41.5 ± 2.5 units
ml-1 b indicated by *) and at 24-h (72 ± 4 units ml-1, c
indicated by *) versus DM control. With palmitate alone, a
significant (P\ 0.05) elevation in JNK activity was observed
(79.5 ± 9.5 units ml-1, b indicated by ?a) at 2-h and
119.5 ± 2.5 units ml-1 at 24-h, c indicated by ?a). JNK
activity continued to rise to 24-h and maximal levels were
reported with high dose TNF-a plus palmitate at 256 ± 10 units
ml-1 (c indicated by ?b). Following co-treatment of palmitate
with FB1 a decrease in JNK activity was observed across the
dose conditions with levels returning to basal in myoblasts
incubated in DM alone, *17 ± 1 units ml-1 (Fig. 8b, c
indicated by #a). With conditions that induced maximal
apoptotic death (high 10 TNF-a), co-treatment of palmitate
with FB1 lowered rates of death and this was mirrored by
significant reductions in JNK activity both at 2-h (b indicated by
#b)and 24-h (c indicated by #b) back to those of basal levels.




Fig. 8 Myoblast signaling associated with EPA, Palmitate and
TNF-a interaction. Palmitate induces lipotoxicity in skeletal
myoblasts through activation of caspase cascades resulting in cell
death and inhibition of differentiation by inducing transcriptional
repression of pro-myogenic transcription factors MyoD, myo-
genin, IGF-II and IGFBP5 whilst activating Id3 associated with
inhibition of differentiation, caspase activation and cell death.
Palmitate alone or palmitate with TNF-a inhibits IGF signalling.
Palmitate in combination with cytokine, TNF-a, induces both
lipotoxic and cytotoxic inflammatory processes resulting in the
activation of MAPK, ceramide and JNK pathways that are
associated with cell death processes. Signal inhibition of
respective pathways using PD98059 and Fumonisin B1 induced
survival. It is proposed lipotoxicity associated with palmitate in
the present study represents a myoblast muscle model of obesity
resulting in impaired regenerative capacity of skeletal muscle.
Combined TNF-a and palmitate represents a proposed model of
sarcopenic obesity whereby chronic elevated inflammation is
associated with sarcopenia and palmitate associated with
increased circulating fatty acids associated with obesity. EPA
administration is able to partially stimulate differentiation with
palmitate alone suggesting in an lipotoxic ‘obese’ environment
EPA can enable myotube formation. In a cytotoxic and lipotoxic
‘sarcopenic obese’ environment EPA can induce partial rescue of
death and differentiation suggesting rescue of death may be due
to dampening on inflammatory processes and myotube formation
due to dampening of lipotoxic processes. EPA also downregu-
lates Id3 expression and correlates with reduced cell death under
conditions of lipotoxicity and cytotoxicity. Thus EPA has




differentiation in all conditions tested. Addition of
palmitate to cyotoxic conditions, high dose TNF-a
alone (10 ng ml-1) acted to further the incidence of
cell death. Biochemical and gene expression analyses
for markers of differentiation showed a decline in
skeletal myoblast creatine kinase activity and IGF-II,
IGFBP5, MyoD and myogenin expression with palmi-
tate pre-treatment. Furthermore, Id3 which functions
as a negative regulator of differentiation by integrating
mitogenic growth factor signalling into the gene
regulatory programme maintaining cell cycle progres-
sion, was highly expressed when myoblasts were
administered with palmitate. Critically, elevated Id3
expression is also associated with increased death in
myoblasts (Atherton et al. 1996). By contrast, EPA
(50 lM) treatment reduced incidence of myoblast
death and in conditions that induced myotube forma-
tion EPA enhanced this response. Addition of EPA to
high dose TNF-a (10 ng ml-1) significantly lowered
the incidence of cell death compared with either
treatment in the absence of EPA and simultaneously
increased biochemical and morphological differenti-
ation, which were reflected by significant increases in
expression of IGF-II, IGFBP-5 and Myogenin.
Having demonstrated opposing effects of EPA
(50 lM) and palmitate (750 lM) upon myoblast
death, specifically EPA protecting myoblasts from
the effects of high dose TNF-a (10 ng ml-1) or
palmitate-induced reductions in differentiation, we
wished to discover if co-incubating EPA with Palmi-
tate could potentially ameliorate the cyotoxic effects
and stimulate myotube formation in high dose TNF-a
(10 ng ml-1) as well as low dose TNF-a (1.25 ng
ml-1) co-incubated with IGF-I compared with palmi-
tate alone. Addition of EPA was able to lower the
induction of cell death in the presence of palmitate
plus TNF-a. Despite this protective effect, the inci-
dence of cell death was still significantly higher than in
the presence of any of the myotoxic triggers alone,
suggesting the activation of pathways resistant to the
protective effects of EPA treatment. Having deter-
mined that EPA was able to elicit a small but
significant effect on the cell death inducing abilities
of palmitate plus TNF-a, we next wished to investigate
the impact of these co-incubations on myoblast fusion.
Co-incuation of palmitate and EPA, elevated creatine
kinase activity compared with palmitate alone sug-
gesting EPA stimulates differentiation. Critically, in
the presence of TNF-a (regardless of the treatment
regime), EPA returned CK activity levels to those seen
in the complete absence of palmitate e.g. it negated the
interaction of palmitate with TNF-a on differentiation.
This is different to the outcome seen with apoptosis,
where cell death levels in the presence of EPA did not
reduce to trigger levels in the absence of palmitate,
suggesting EPA is more potent at protecting against
the palmitate/TNF-a-induced block on differentiation
than induction of cell death.
In parallel with increased creatine kinase activity
co-treatment of palmitate with EPA also elevated IGF-
II, IGFBP-5, MyoD, Myogenin but did not suppress
the expression of Id3. The findings suggest EPA is
capable of partially rescuing the inhibitory impact of
palmitate on differentiation potentially via genes
associated with myotube formation but does not
involve suppression of Id3 at the time-points investi-
gated. Although gene expression, biochemical and
morphological analyses were conducted up to 72 h, it
is possible that measurement of markers of differen-
tiation at 96- and 120-h may have been rescued at
these latter time points with addition of EPA to
palmitate. Nonetheless, this would have indicated that
the capacity to form myotubes is delayed/impeded in
the context of regenerating muscle.
Mechanisms for palmitate-induced cell death
associated with TNF-a and IGF-I interaction
in skeletal myoblasts
Cytotoxic accumulation of long chain fatty acids have
been proposed to play an important role in the
pathogenesis of diabetes mellitus, heart disease and
potentially sarcopenic obestiy. To explore the mech-
anism of cellular lipotoxicity, studies by Listenberger
et al. (Listenberger et al. 2001) have demonstrated in
the presence of media supplemented with fatty acid,
the saturated fatty acid palmitate, induces pro-
grammed cell death as determined by annexin V
positivity, caspase 3 activity, and DNA laddering. We
determined whether caspase activation was involved
in the cell death effect of palmitate addition. Whilst
the addition of palmitate significantly increased
(P\ 0.05) caspase activity, indicating that palmitate
may induce cell death via a caspase mediated mech-
anism, EPA only partially reduced the impact of
palmitate on caspase activation and caspase inhibition
where the use of Z- VDVAD-FMK (caspase),
Z-DEVD-FMK (caspase), Z-IETD-FMK (caspase 8)
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inhibitors only partially reduced the incidence of
myoblast death. Interestingly, it is reported that Id-3 is
capable of inducing apoptosis via caspase-mediated
pathways (Kee 2005; Norton and Atherton 1998;
Simbulan-Rosenthal et al. 2006). The inability of EPA
to significantly reduce palmitate-induced Id-3 expres-
sion, may be linked to sustained caspase activation and
maintained apoptosis in the presence of palmitate plus
EPA.
Having demonstrated that EPA does not reduce Id-
3 expression or DNA fragmentation and that individ-
ual caspase inhibition did not significantly reduce
myoblast death following palmitate pre-treament, we
explored whether alternative signalling pathways may
be involved. Previously we have suggested a novel
role for MAP kinase in ceramide-induced apoptosis as
well as the up-regulation of the c-Jun N terminal-
kinase (JNK) signalling pathway in TNF-a-induced
cell death (Stewart et al. 1999b), palmitate uptake
(Sabin et al. 2007) and myoblast models of ageing
(Sharples et al. 2011). We therefore wished to
investigate whether MAPKs and JNK were involved
in palmitate mediated apoptosis in the present model.
Specifically, we have shown that C2, C2C12 and
human skeletal myoblasts are susceptible to apoptotic
death, in a dose responsive fashion to TNF-a (Foul-
stone et al. 2001, 2004; Saini et al. 2008; Sharples et al.
2010; Stewart et al. 2004). In C2 cells, optimal
cyotoxicity was identified at 10 ng ml-1 TNF-a. The
capacity of the cells to differentiate and to form
myotubes was blocked even at 1.25 ng ml-1 TNF-a
which does not induce apoptosis (Saini et al. 2008). Co-
incubationwith IGF-I (1.5 ngml-1) was able to reduce
the apoptotic effects of high dose TNF-a (10 ng ml-1)
but not rescue the block on differentiation. Myotube
formation and creatine kinase activity were also
blocked by 1.25 ng ml-1 TNF-a (Saini et al. 2008).
As predicted, media supplemented with palmitate
significantly elevated cell death across the treatment
groups: DM, low dose TNF-a and IGF-I alone. This
was further elevated in conditions where apoptosis was
already elevated (high dose TNF-a) causing an
increase in cell death. This increase was however,
blocked by a pre-incubation with PD98059 (20 lM).
AlthoughMAPK activity was not assessed directly, we
have previously reported a reduction in MEK-ERK1/2
activation following PD98059 administration at these
doses and in this model (Al-Shanti and Stewart 2008;
Alessi et al. 1995; Saini et al. 2008).Where PD98059 in
palmitate samples was effective in lowering rates of
cell death to levels comparable to control conditions.
Basal cell death following MAPK inhibition averaged
13 ± 3% for DM, low dose TNF and IGF-I alone. In
conditions associated with maximal apoptotic death
(high dose TNF) was reduced to 28 ± 2%. The above
findings therefore suggest MAPK to be a central
component for the induction of apoptosis under
cytotoxic and/or lipotoxic conditions.
Evidence also suggests the role of ceramide func-
tioning downstream of palmitate and TNF-a but
upstream of the MAPK pathway, which potentially
acts as a master regulator of lipid- and cytokine-
induced apoptosis. Intracellular accumulation of long
chain fatty acids in non- adipose tissues is associated
with cellular dysfunction and cell death and may
ultimately contribute to the pathogenesis of disease
(Listenberger et al. 2001). It has been hypothesised
that FFAs are precursors for de novo ceramide
synthesis, it has also been hypothesised that fatty
acid- induced apoptosis occurs through this pathway.
Indeed, studies have previously shown that saturated
fatty acids induce de novo ceramide accumulation and
apoptosis in cultured myotubes (Turpin et al. 2006).
Extensive evidence shows that saturated fatty acids
can induce apoptosis in several cell types including
pancreatic b-cells, hepatocytes, cardiomyocytes and
skeletal muscle myotubes in vitro (Hickson-Bick et al.
2000; Shimabukuro et al. 1998; Turpin et al. 2006;
Wei et al. 2006). Fatty acid-induced apoptosis, or
‘lipo-apoptosis’, causes changes in tissue function.
Ceramide is a lipid second messenger involved in the
apoptotic response induced by TNF-a, ionising radi-
ation and heat shock (Kolesnick and Kronke 1998).
These stimuli are thought to increase ceramide by
hydrolysis of sphingomyelin rather than de novo
biosynthesis. The downstream signalling pathways
through which ceramide initiates apoptosis remain
unclear, but several possible components have been
identified. Direct targets of ceramide include cera-
mide-activated protein kinase (CAPK, KSR), protein
kinase C, and ceramide-activated protein phosphatase
(Mathias et al. 1998). Ceramide signalling is affected
by mitogen- activated protein kinase (our findings
support a role of the MAPK system in myoblast
apoptosis) and c-Jun N-terminal kinase (JNK) sig-
nalling cascades ultimately leading to growth arrest




Under control conditions basal JNK activity was
observed with DM treatment. In conditions where
myoblast cell death was observed, high dose TNF-a
administration, JNK phosphorylation was signifi-
cantly elevated. Pre-treatment with palmitate further
elevated JNK activity even under basal conditions,
suggesting palmitate induces death through JNK
phosphorylation. Following co-treatment of palmitate
with FB1 (FumonisinB1 which blocks ceramide
synthase and thereby ceramide accumulation) there
was a reduction in the incidence of myoblast death that
was accompanied by a decrease in JNK phosphoryla-
tion. Although cell death was still elevated above basal
conditions for DM, low dose TNF-a alone and IGF-I
alone (16 ± 1, 18 ± 3, and 16 ± 1%, respectively)
this was significantly below the same treatments
administered with palmitate in the absence of FB1.
Maximal apoptotic death with high dose TNF-a alone
(10 ng ml-1) had been lowered to 15 ± 4% and was
accompanied by 66 ± 7% decrease in JNK activity.
These findings suggest that the mechanisms by which
palmitate induced death in these models is the result of
ceramide and JNK activity.
Lipotoxicity is a commonly used term that broadly
describes detrimental changes to cell morphology and
function induced by an excess of fatty acids and/or
intracellular accumulation of lipids that may cause cell
death. There is no doubt that lipotoxicity, as originally
defined, is evident in the pancreas, liver and possibly
the heart (Garris 2005; Shimabukuro et al. 1998;
Sparagna et al. 2000; Summers 2006; Wei et al. 2006).
Likewise, lipid overload undoubtedly disrupts some
aspects of skeletal muscle function, such as insulin
signal transduction. This study was undertaken to
specifically determine whether an excess of lipids
causes apoptosis in skeletal muscle, and whether these
events are related to changes in muscle morphology.
Our studies indicate that acute fatty acid overload can
promote pro- apoptotic signaling and significantly
reduce the ability of myoblasts to differentiate. This
therefore warrants exploration in the context of in vivo
adult muscle regeneration. Fatty acid-induced apop-
tosis may therefore contribute to skeletal myoblast
death associated with sarcopenic obesity. Palmitate
induces myoblast apoptosis potentially through altered
Id-3 mRNA expression, caspase activation and/or,
ceramide, MAPK and JNK pathways and the inhibi-
tion of differentiation is characterized via suppression
of key regulatory myogenic factors, such as myogenin,
myoD, IGF-II and IGFBP-5 (Fig. 8). By contrast EPA
does appear to have a protective action against MAPK
mediated cell death and reduced differentiation but not
against Id3/caspase-induced apoptosis (Fig. 8).
In the present study we propose that the actions of
palmitate alone represent a model of the effects of
obesity in regenerating skeletal muscle where
increased fatty acid levels are associated with cell
death and reduced differentiation, thus impacting on
the regenerative capacity of muscle. Combined with
the cytokine, TNF-a, we propose that the cell models
represent a sarcopenic obese environment, given that
chronic elevated inflammation is a characteristic of
ageing muscle and increased fatty acid infiltration is a
characteristic of obese muscle. As demonstrated in our
study, the sarcopenic obese model induced the greatest
impact on cell death and differentiation (Fig. 8).
These findings support further investigations of
EPA as a potential therapeutic agent in conditions
associated with elevated saturated fat, cytokine
inflammation and reduced muscle mass indicative of
sarcopenic obesity.
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